Resource utilization with insulin pump therapy for type 2 diabetes mellitus

American Journal of Managed Care

Volumn 16, Issue 12, 2010, Pages 892-896

  Lynch, Peter M ^a   Riedel, Aylin Altan ^b   Samant, Navendu ^b   Fan, Ying ^b   Peoples, Tim ^a   Levinson, Jenifer ^a   Lee, Scott W ^a  

^a MEDTRONIC INC   (United States)

^b i3 Innovus   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; INSULIN; METFORMIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE;

ADULT; ARTICLE; EMERGENCY WARD; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; INSULIN INFUSION; INSULIN PUMP; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH RESOURCES; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INPATIENTS; INSULIN; INSULIN INFUSION SYSTEMS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 78650956112     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Nathan DM, Buse JB, David son MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [published correction appears in: Diabetes Care. 2006;29(11):2816-2818]. Diabetes Care. 2006;29(8):1963-1972.
2. Huang ES, Gleason S, Gaudette R, et al. Health care resource utilization associated with a diabetes center and a general medicine clinic. J Gen Intern Med. 2004;19(1):28-35.
3. Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy. 2008;6(2-3):103-112.
4. Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care. 2003;26(8):2300-2304.
5. Berthe E, Lireux B, Coffin C, et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res. 2007;39(3):224-229.
6. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28(7):1568-1573.
7. Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. Exp Clin Endocrinol Diabetes. 2009;117(5):220-222.
8. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26(9):2598-2603.
9. Wainstein J, Metzger M, Boaz M, et al. Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabet Med. 2005;22(8):1037-1046.
10. Centers for Medicare and Medicaid Services. Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf. Accessed May 4, 2010.
11. Lynch P, Riedel AA, Samant N, Fan Y, Peoples T, Lee SW. Improved A1C by switching to continuous subcutaneous insulin infusion from injection insulin therapy in type 2 diabetes: a retrospective claims analysis [published online ahead of print September 8, 2010]. Prim Care Diabetes. doi:10.1016/j.pcd.2010. 07.004. Medline:20832374.